Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non Operating Income: 2016-2025

Historic Other Non Operating Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$1.0 million.

  • Ultragenyx Pharmaceutical's Other Non Operating Income fell 133.90% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 199.17%. This contributed to the annual value of -$4.0 million for FY2024, which is 1075.96% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Other Non Operating Income of -$1.0 million as of Q3 2025, which was down 148.74% from $2.1 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Other Non Operating Income high stood at $3.1 million for Q3 2024, and its period low was -$3.6 million during Q4 2024.
  • For the 3-year period, Ultragenyx Pharmaceutical's Other Non Operating Income averaged around -$215,091, with its median value being -$699,000 (2023).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Other Non Operating Income slumped by 1,288.06% in 2022 and then skyrocketed by 1,035.00% in 2023.
  • Ultragenyx Pharmaceutical's Other Non Operating Income (Quarterly) stood at -$410,000 in 2021, then skyrocketed by 143.90% to $180,000 in 2022, then surged by 1,035.00% to $2.0 million in 2023, then crashed by 276.51% to -$3.6 million in 2024, then plummeted by 133.90% to -$1.0 million in 2025.
  • Its last three reported values are -$1.0 million in Q3 2025, $2.1 million for Q2 2025, and $837,000 during Q1 2025.